Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.
Nikolaos G PapadopoulosStanley J SzeflerLeonard B BacharierJorge F MasperoChristian DomingoAlessandro Giovanni FiocchiJason K LeeNadia DaizadehDavid J LedererMegan HardinRebecca GallMichel DjandjiShahid SiddiquiJuby A Jacob-NaraYamo DenizPaul J RowePublished in: Allergy (2023)
Dupilumab vs placebo reduced asthma exacerbations in children with type 2 asthma irrespective of evidence of allergic asthma; similar trends were observed in changes in lung function. Significant improvement in asthma control was observed in patients with evidence of allergic asthma, but not in those without.